An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

Inclusion Criteria:

1. Completion of a Cytokinetics trial investigating CK-3773274
2. LVEF ≥55% at the Screening Visit

Exclusion Criteria:

1. Has participated in another investigational device or drug study or received aninvestigational device or drug <1 month (or 5 half-lives for drugs, whichever islonger) prior to screening. Other investigational procedures while participating inthis study are not permitted.
2. Since completion of a previous study of aficamten has:Developed new-onset paroxysmalor permanent atrial fibrillation (AF) requiring rhythm restoring treatment (e.g.,direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) <30 daysprior to screening. Patient may rescreen for JX01003 after 30 days if heart rate (HR) <100 bpm and/or rhythm is stable >30 days.
3. Undergone septal reduction therapy (surgical myectomy or transcatheter alcoholablation).
4. Had a confirmed LVEF <40% with an associated dose interruption during participation ina prior study with aficamten.
5. History of appropriate implantable cardioverter defibrillator (ICD) shock within 30days prior to screening.
6. Has received treatment with mavacamten.